PRINTED: 07/24/2025 FORM APPROVED

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:		(X2) MULTIPLE ( A. BUILDING:		(X3) DATE SURVEY COMPLETED		
		MHL001-165	B. WING		07/	23/2025
NAME OF P	ROVIDER OR SUPPLIER		DDRESS, CITY, STAT	E, ZIP CODE		
NEW DIMI	ENSIONS INTERVENTIO	NS INC	DERSON ROAD GTON, NC 27217			
(X4) ID PREFIX TAG	(EACH DEFICIENC	ATEMENT OF DEFICIENCIES Y MUST BE PRECEDED BY FULL LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF COR (EACH CORRECTIVE ACTION S CROSS-REFERENCED TO THE A DEFICIENCY)	SHOULD BE	(X5) COMPLETE DATE
V 000	INITIAL COMMENTS	3	V 000			
	2025. A deficiency was This facility is license categories: 10A NCA Living for Adults with This facility is license	d for the following service C 27G .5600A Supervised Mental Illness. d for 5 and has a current yey sample consisted of				
V 121	governing body or op for obtaining a review regimen at least ever shall be to be perforn physician. The on-site the client's physician the review when med	es psychotropic drugs, the erator shall be responsible of each client's drug y six months. The review ned by a pharmacist or e manager shall assure that is informed of the results of lical intervention is indicated. e drug regimen review shall ent record along with	V 121			
	facility failed to obtain six months for 3 of 3 received psychotropic	as evidenced by: views and interview, the n drug regimen reviews every clients (#1, #2 and #3) who c drugs. The findings are:				

Division of Health Service Regulation
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE

TITLE (X6) DATE

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION		(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION		(X3) DATE SURVEY COMPLETED		
		A. BUILDING:					
MHL001-165		B. WING		07/23/2025			
NAME OF PI	ROVIDER OR SUPPLIER	STREET AL	DRESS, CITY, STA	TE, ZIP CODE			
NEW DIMI	ENSIONS INTERVENTIO	NS INC 2856 AND	ERSON ROAD				
NEW DIMENSIONS INTERVENTIONS, INC BURLINGTON, NC 27217							
(X4) ID PREFIX TAG	(EACH DEFICIENC	ATEMENT OF DEFICIENCIES Y MUST BE PRECEDED BY FULL LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD CROSS-REFERENCED TO THE APPROPE DEFICIENCY)	BE COMPLETE		
V 121	Continued From page	e 1	V 121				
	-Admission date of 4/						
	Invega Trinza 819 mi (Schizophrenia), admintramuscularly every Ferrous Sulfate 325n mouth once daily Chlorthalid 25mg (Bloby mouth once daily Lisinopril 5mg (Blood mouth once daily Aspirin 81mg (Cardio mouth once daily Folic Acid 1000mcg (mouth once daily Vitamin D2 50000 un once a week	ninister 2.625ml					
	daily Divalproex 500mg, ta daily Quetiapine 50mg (Ar mouth at bedtime -Physician's order da Varenicline 1mg (Sm mouth once daily -Physician's order da Benztropine 0.5mg, t daily	te 1 tablet by mouth once  ke 2 tablets by mouth twice  tipsychotic), take 1 tablet by  ted 4/3/25 for the following:  oking), take 1 tablet by  ted 5/12/25 for the following:  ake 1 tablet by mouth twice					
-There was no evidence of a current six month psychotropic drug review.							

Division of Health Service Regulation

STATE FORM 6899 CY1F11 If continuation sheet 2 of 5

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION  (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:		1 ` ′	(X2) MULTIPLE CONSTRUCTION  A. BUILDING:		(X3) DATE SURVEY COMPLETED	
MHL001-165			B. WING	B. WING		
NAME OF F	ROVIDER OR SUPPLIER	STREE	ET ADDRESS, CITY, STA	TE, ZIP CODE		
I NEW DIMENSIONS INTERVENTIONS. INC			ANDERSON ROAD LINGTON, NC 2721	7		
(X4) ID PREFIX TAG	(EACH DEFICIENC	ATEMENT OF DEFICIENCIES Y MUST BE PRECEDED BY FULL SC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN ( (EACH CORRECTIVE A CROSS-REFERENCED T DEFICIE	CTION SHOULD BE O THE APPROPRIATE	(X5) COMPLETE DATE
V 121	Review on 7/22/25 of July 22, 2025 Medica (MAR) revealed: -Staff documented CI the above medication July 22, 2025.  Review on 7/22/25 of -Admission date of 8/-Diagnoses of Schizo Intellectual Developm Elevated Liver Enzym-Physician's order dar Invega Trinza 819 mil (Schizophrenia), Injection, Injection, Injection and Invega Trinza 819 mil (Schizophrenia), Injection, Injection and Invega Trinza 819 mil (Schizophrenia), Injection, Injecti	the May 1, 2025 through tion Administration Record ient #1 was administered from May 1, 2025 through  Client #2's record revealed: 16/17. affective Disorder, mental Disability, Mild, mes. ted 6/12/25 for the following: lligrams (mg) at 819mg once every 90 act 0.5ml intramuscularly for tholesterol), take 1 tablet by ale 1 inhalation by mouth chizophrenia), take 1 tablet tidepressant), take 1 tablet vital via nebulizer for times ke 2 tablets by mouth at ted 4/7/25 for the following: s, take 1 tablet by mouth take 1 tablet by mouth once conth psychotropic drug d was 12/30/24. Ince of a current six month	V 121			

Division of Health Service Regulation

STATE FORM 6899 CY1F11 If continuation sheet 3 of 5

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION		(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	` '	CONSTRUCTION		(X3) DATE SURVEY COMPLETED	
AND PLAN OF CORRECTION IDENTIFICATION NUMBER:		A. BUILDING: _		COMP	LETED		
MHL001-165		B. WING	B. WING		07/23/2025		
NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE							
NEW DIM	ENSIONS INTERVENTIO	NS INC	DERSON ROAD				
NEW DIM	ENGIONO INTERVENTIO	BURLING	STON, NC 27217	7			
(X4) ID PREFIX TAG	(EACH DEFICIENC	ATEMENT OF DEFICIENCIES Y MUST BE PRECEDED BY FULL LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF (EACH CORRECTIVE AC CROSS-REFERENCED TO DEFICIEN	TION SHOULD BE THE APPROPRIATE	(X5) COMPLETE DATE	
V 121	Continued From page	e 3	V 121				
	Review on 7/22/25 of July 22, 2025 MAR re -Staff documented Cl	the May 1, 2025 through					
	-Admission date of 7/ -Diagnoses of Schizo Intellectual Disability, Hypercholesterolemia -Physician's order da Omega-3 1000mg, ta daily Ketoconazole 2% (Sh while shampooing ha Haloper Injection 100 intramuscularly every Clozapine 100mg (So tablets by mouth once Vitamin D3 5000 unit once daily Cetirizine 10mg (Alle mouth once daily Aspirin 81mg, take 1 Atorvastatin 20mg (C mouth once daily Mbivent Respimat 20 mouth twice daily	paffective Disorder, Mild COPD, and a ted 6/12/25 for the following: like 1 capsule by mouth once mampoo), use once a day ir limg, inject 1 ml or four weeks chizophrenia), take 2 ½					
	Clozapine 100mg (So by mouth at bedtime Metoprol Suc 25mg ( tablet by mouth at be Lithium 300mg, take bedtime	2 tablets by mouth at ipsychotic), take 1 tablet by					
-The last time a six month psychotropic drug							

Division of Health Service Regulation

STATE FORM 6899 CY1F11 If continuation sheet 4 of 5

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION  (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:		(X2) MULTIPLE A. BUILDING: _	CONSTRUCTION		(X3) DATE SURVEY COMPLETED	
MHL001-165		B. WING			07/23/2025	
NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE						
I NEW DIMENSIONS INTERVENTIONS, INC			ERSON ROAD TON, NC 27217	7		
(X4) ID PREFIX TAG	(EACH DEFICIENC	ATEMENT OF DEFICIENCIES Y MUST BE PRECEDED BY FULL .SC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF (EACH CORRECTIVE AC CROSS-REFERENCED TO DEFICIEN	TION SHOULD BE THE APPROPRIATE	(X5) COMPLETE DATE
V 121	review was conducted.  There was no evider psychotropic drug review on 7/22/25 of July 22, 2025 MAR restant documented Clithe above medication July 22, 2025.  Interview on 7/22/25 or revealed:  -"The clients missed to appointment due to bound was a complete their medication."  -"The pharmacy has seed to complete their medication."  -"All the clients have a complete their medication."	d was 12/30/24. Ince of a current six month riew.  Ithe May 1, 2025 through evealed: Itent #3 was administered from May 1, 2025 through  With the Assistant Director Itheir pharmacy review eing out of town on  Iso many large group homes lication reviews, it took a ome to get rescheduled." Itheen rescheduled for August dication review." Ithe psychotropic drug Ithe the through the psychotropic drug Ithe the through the through the psychotropic drug Ithe through the through the through the psychotropic drug Ithe through through the through the through the through the through through through the through through the through through the through through through through the through through through the through through through the through through through the through through through through through through through the through thro	V 121			

Division of Health Service Regulation

STATE FORM 6899 CY1F11 If continuation sheet 5 of 5